Cargando…

Activation mechanisms of clinically distinct B‐Raf V600E and V600K mutants

Detalles Bibliográficos
Autores principales:	Zhang, Mingzhen, Maloney, Ryan, Liu, Yonglan, Jang, Hyunbum, Nussinov, Ruth
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Letters to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10009660/ https://www.ncbi.nlm.nih.gov/pubmed/36573259 http://dx.doi.org/10.1002/cac2.12395

Ejemplares similares

The mechanism of activation of monomeric B-Raf V600E
por: Maloney, Ryan C., et al.
Publicado: (2021)

The mechanism of activation of MEK1 by B-Raf and KSR1
por: Maloney, Ryan C., et al.
Publicado: (2022)

The mechanism of Raf activation through dimerization
por: Zhang, Mingzhen, et al.
Publicado: (2021)

Small molecules against B-RAF (BRAF) Val600Glu (V600E) single mutation
por: Zaharie, Florin, et al.
Publicado: (2015)

The quaternary assembly of KRas4B with Raf-1 at the membrane
por: Jang, Hyunbum, et al.
Publicado: (2020)

Deconvoluting Mechanisms of Acquired Resistance to RAF Inhibitors in BRAF(V600E)-Mutant Human Glioma
por: Schreck, Karisa C., et al.
Publicado: (2021)

Suppression of B-Raf(V600E) cancers by MAPK hyper-activation
por: Atiq, Rawan, et al.
Publicado: (2016)

Does Ras Activate Raf and PI3K Allosterically?
por: Nussinov, Ruth, et al.
Publicado: (2019)

The structural basis of BCR-ABL recruitment of GRB2 in chronic myelogenous leukemia
por: Liu, Yonglan, et al.
Publicado: (2022)

Low‐grade BRAF V600E mutant oligodendroglioma‐like tumors of children may show EGFR and MET amplification
por: Yang, Rui Ryan, et al.
Publicado: (2020)

Insight on BRAF(V600E) mutated colorectal cancer immune microenvironment
por: Abushukair, Hassan Mohammed, et al.
Publicado: (2022)

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
por: Poulikakos, Poulikos I., et al.
Publicado: (2011)

Novel natural inhibitors targeting B-RAF(V600E) by computational study
por: Wu, Bo, et al.
Publicado: (2021)

600 kV generator
por: CERN PhotoLab
Publicado: (1965)

AlphaFold, Artificial Intelligence (AI), and Allostery
por: Nussinov, Ruth, et al.
Publicado: (2022)

Higher‐order interactions of Bcr‐Abl can broaden chronic myeloid leukemia (CML) drug repertoire
por: Liu, Yonglan, et al.
Publicado: (2023)

Strategy toward Kinase-Selective Drug Discovery
por: Zhang, Mingzhen, et al.
Publicado: (2023)

The mechanism of PI3Kα activation at the atomic level
por: Zhang, Mingzhen, et al.
Publicado: (2019)

Ras isoform-specific expression, chromatin accessibility, and signaling
por: Nussinov, Ruth, et al.
Publicado: (2021)

A Look Inside of the Complex Pathogenesis of B-RAF(V600E)-Driven Cancer
por: Caputo, Emilia
Publicado: (2017)

Autoinhibition in Ras effectors Raf, PI3Kα, and RASSF5: a comprehensive review underscoring the challenges in pharmacological intervention
por: Nussinov, Ruth, et al.
Publicado: (2018)

Pan-RAF and MEK vertical inhibition enhances therapeutic response in non-V600 BRAF mutant cells
por: Molnár, Eszter, et al.
Publicado: (2018)

Stability of BRAF V600E mutation in metastatic melanoma: new insights for therapeutic success?
por: Sigalotti, L, et al.
Publicado: (2011)

BRAF V600E and MAP2K1 Mutations in Hairy Cell Leukemia and Splenic Marginal Zone Lymphoma Cases
por: Shin, Sang-Yong, et al.
Publicado: (2015)

PI3K inhibitors: review and new strategies
por: Zhang, Mingzhen, et al.
Publicado: (2020)

Analysis of the B-RAF(V600E) mutation in cutaneous melanoma patients with occupational sun exposure
por: CANDIDO, SAVERIO, et al.
Publicado: (2014)

Melanoma whole exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance
por: Shi, Hubing, et al.
Publicado: (2012)

Current Controversies and Challenges on BRAF V600K-Mutant Cutaneous Melanoma
por: Nepote, Alessandro, et al.
Publicado: (2022)

BRAF V600E Inhibitor (Vemurafenib) for BRAF V600E Mutated Low Grade Gliomas
por: Del Bufalo, Francesca, et al.
Publicado: (2018)

B-RafV600E inhibits sodium iodide symporter expression via regulation of DNA methyltransferase 1
por: Choi, Yong Won, et al.
Publicado: (2014)

Synchronous and Metachronous Thyroid Cancer in Relation to Langerhans Cell Histiocytosis; Involvement of V600E BRAF-Mutation?
por: Moschovi, Maria, et al.
Publicado: (2015)

Cell cycle progression mechanisms: slower cyclin-D/CDK4 activation and faster cyclin-E/CDK2
por: Zhang, Wengang, et al.
Publicado: (2023)

An approach to suppress the evolution of resistance in BRAF(V600E)-mutant cancer
por: Xue, Yaohua, et al.
Publicado: (2017)

Acquired resistance to BRAF inhibition in BRAF(V600E) mutant gliomas
por: Yao, Tsun-Wen, et al.
Publicado: (2016)

Allosteric regulation of autoinhibition and activation of c-Abl
por: Liu, Yonglan, et al.
Publicado: (2022)

[600 MeV]
por: CERN Press Office. Geneva
Publicado: (1962)

BRAF V600K vs. BRAF V600E: a comparison of clinical and dermoscopic characteristics and response to immunotherapies and targeted therapies
por: Zengarini, Corrado, et al.
Publicado: (2022)

Discrepant Results for BRAF V600E Mutation Among Different Specimens in a Case of Hairy Cell Leukemia
por: Moon, Hee-Won, et al.
Publicado: (2013)

Circulating cell-free BRAF V600E during chemotherapy is associated with prognosis of children with Langerhans cell histiocytosis
por: Cui, Lei, et al.
Publicado: (2020)

BRAF V600E-positive cells as molecular markers of bone marrow disease in pediatric Langerhans cell histiocytosis
por: Kudo, Ko, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rit7ta5i9rdgupfgrt6g1sihsd